NCT06844669 2026-03-03
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Washington University School of Medicine
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT03879629 2025-11-20
Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
Mayo Clinic
Phase 2 Active not recruiting
NCT04023110 2025-10-09
CCTGuide Pilot
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03418961 2025-10-08
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04190433 2023-05-24
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
Mayo Clinic
Phase 2 Withdrawn
NCT02177175 2022-07-12
Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01009918 2021-03-30
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
University of South Florida
Phase 2 Completed
NCT01724450 2018-02-05
Ceccy
University of Sao Paulo
Phase 3 Completed